Jan 21, 2022 / 01:30AM GMT
Tim Oldham - AdAlta Limited - CEO and MD
Thanks, Tim. Thanks for having us today. Just a quick summary of where AdAlta is up to right now. As Tim mentioned, we are a drug discovery and development company. Our mission in life is to create therapeutics that improve the health of our patients. We do this using our i-body platform, which is our drug discovery tool, and we believe this is a novel way of creating therapeutics against targets that traditional antibody approaches have struggled with.
We've so far created four assets from that platform, two that we wholly own in the field of fibrosis and inflammation. The lead asset is AD-214 which has completed Phase I clinical studies and is being prepared for Phase II in a disease called idiopathic pulmonary fibrosis. And we've just started discovery in our second target in that same space.
And then we have two co-development collaborations with other biopharmaceutical companies. The first is with GE Healthcare to develop novel PET imaging agents for immuno-oncology. This is a preclinical stage asset. And the final one is a collaboration with
Adalta Ltd Participates at Sharecafe Small Cap Hidden Gems - Webinar Transcript
Jan 21, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers